AtriCure (ATRC) receives FDA approval for a three-year post approval study for its AtriCure...
Wednesday, September 12, 2012, 6:08 PM ETAtriCure (ATRC) receives FDA approval for a three-year post approval study for its AtriCure Synergy Ablation System, called Ablate, used for the surgical treatment of Atrial Fibrillation. The follow-up study is intended to build additional evidence on the safety, efficacy and long-term durability of the Maze IV concomitant treatment for AF using AtriCure’s proprietary surgical devices.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles